» Articles » PMID: 33006750

BRD4 Modulates Vulnerability of Triple-negative Breast Cancer to Targeting of Integrin-dependent Signaling Pathways

Abstract

Purpose: Stemming from a myriad of genetic and epigenetic alterations, triple-negative breast cancer (TNBC) is tied to poor clinical outcomes and aspires for individualized therapies. Here we investigated the therapeutic potential of co-inhibiting integrin-dependent signaling pathway and BRD4, a transcriptional and epigenetic mediator, for TNBC.

Methods: Two independent patient cohorts were subjected to bioinformatic and IHC examination for clinical association of candidate cancer drivers. The efficacy and biological bases for co-targeting these drivers were interrogated using cancer cell lines, a protein kinase array, chemical inhibitors, RNAi/CRISPR/Cas9 approaches, and a 4 T1-Balb/c xenograft model.

Results: We found that amplification of the chromosome 8q24 region occurred in nearly 20% of TNBC tumors, and that it coincided with co-upregulation or amplification of c-Myc and FAK, a key effector of integrin-dependent signaling. This co-upregulation at the mRNA or protein level correlated with a poor patient survival (p < 0.0109 or p < 0.0402, respectively). Furthermore, we found that 14 TNBC cell lines exhibited high vulnerabilities to the combination of JQ1 and VS-6063, potent pharmacological antagonists of the BRD4/c-Myc and integrin/FAK-dependent pathways, respectively. We also observed a cooperative inhibitory effect of JQ1 and VS-6063 on tumor growth and infiltration of Ly6G myeloid-derived suppressor cells in vivo. Finally, we found that JQ1 and VS-6063 cooperatively induced apoptotic cell death by altering XIAP, Bcl2/Bcl-xl and Bim levels, impairing c-Src/p130Cas-, PI3K/Akt- and RelA-associated signaling, and were linked to EMT-inducing transcription factor Snail- and Slug-dependent regulation.

Conclusion: Based on our results, we conclude that the BRD4/c-Myc- and integrin/FAK-dependent pathways act in concert to promote breast cancer cell survival and poor clinical outcomes. As such, they represent promising targets for a synthetic lethal-type of therapy against TNBC.

Citing Articles

Focal adhesion in the tumour metastasis: from molecular mechanisms to therapeutic targets.

Liu Z, Zhang X, Ben T, Li M, Jin Y, Wang T Biomark Res. 2025; 13(1):38.

PMID: 40045379 PMC: 11884212. DOI: 10.1186/s40364-025-00745-7.


Comprehensive dissection of cis-regulatory elements in a 2.8 Mb topologically associated domain in six human cancers.

Caragine C, Le V, Mustafa M, Diaz B, Morris J, Muller S Nat Commun. 2025; 16(1):1611.

PMID: 39948336 PMC: 11825950. DOI: 10.1038/s41467-025-56568-5.


BET inhibitors (BETi) influence oxidative phosphorylation metabolism by affecting mitochondrial dynamics leading to alterations in apoptotic pathways in triple-negative breast cancer (TNBC) cells.

Rossi T, Iorio E, Chirico M, Pisanu M, Amodio N, Gallo Cantafio M Cell Prolif. 2024; 57(12):e13730.

PMID: 39223828 PMC: 11628750. DOI: 10.1111/cpr.13730.


Synergistic effects of combined BET and FAK inhibition against Vestibular Schwannomas in NF2-related Schwannomatosis.

Gonzalez-Rodriguez M, Troutman S, Bayle S, Lester D, Grove M, Duckett D Oncogene. 2024; 43(40):2995-3002.

PMID: 39209965 DOI: 10.1038/s41388-024-03144-8.


Divergent Processing of Cell Stress Signals as the Basis of Cancer Progression: Licensing NFκB on Chromatin.

Vlahopoulos S Int J Mol Sci. 2024; 25(16).

PMID: 39201306 PMC: 11354898. DOI: 10.3390/ijms25168621.


References
1.
Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y . Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-67. PMC: 3127435. DOI: 10.1172/JCI45014. View

2.
Marsh T, Wong I, Sceneay J, Barakat A, Qin Y, Sjodin A . Hematopoietic Age at Onset of Triple-Negative Breast Cancer Dictates Disease Aggressiveness and Progression. Cancer Res. 2016; 76(10):2932-43. PMC: 8504438. DOI: 10.1158/0008-5472.CAN-15-3332. View

3.
Pereira B, Chin S, Rueda O, Vollan H, Provenzano E, Bardwell H . The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016; 7:11479. PMC: 4866047. DOI: 10.1038/ncomms11479. View

4.
Berger A, Korkut A, Kanchi R, Hegde A, Lenoir W, Liu W . A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. 2018; 33(4):690-705.e9. PMC: 5959730. DOI: 10.1016/j.ccell.2018.03.014. View

5.
Ciriello G, Gatza M, Beck A, Wilkerson M, Rhie S, Pastore A . Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell. 2015; 163(2):506-19. PMC: 4603750. DOI: 10.1016/j.cell.2015.09.033. View